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Abstract
Purpose of Review The goal of this paper is to review current and future uses of patient-reported outcomes in large vessel
vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types of
systemic vasculitis which affect the larger blood vessels. Patient-reported outcomes (PROs) capture the impact of
these diseases on health-related quality of life.
Recent Findings Generic PROs such as the SF-36 are currently used to compare HRQOL of people with GCA and TAK within
clinical trials and observational studies and to make comparisons with the general population and HRQoL in other diseases. The
development of a disease-specific PRO for GCA is currently underway. Beyond clinical trials, there is much interest in the use of
PROs within routine clinical care, particularly E-PROs for remote use.
Summary Further work will be needed to complete the development of disease-specific PROs for people with large vessel
vasculitis and to establish feasibility, acceptability, and utility of E-PROs.
Keywords Giant cell arteritis . Takayasu arteritis . Patient reported outcome . Clinical trials . Outcomes . Large vessel vasculitis
Introduction
The 2012 International Chapel Hill Consensus Conference for
nomenclature of the systemic vasculitides defines the large
vessel vasculitides (LVVs) as giant cell arteritis (GCA) and
Takayasu arteritis (TA) [1]. These are the primary systemic
vasculitides and are characterized by inflammation of the aor-
ta, and its proximal branches accompanied by systemic in-
flammation with elevation in several circulating cytokines in-
cluding interleukin (IL)-6. Other systemic diseases, including
IgG4 disease, may also cause inflammation of the large ves-
sels including the aorta, but these are considered secondary
vasculitides and are outside the scope of this review as their
clinical manifestations in other organ systems must also be
considered. The challenge with large vessel vasculitis (LVV)
is that inflammation of the aorta and its proximal branches
may be asymptomatic or present with seemingly vague symp-
toms such as malaise, fatigue, weight loss, fever, or myalgia.
Consequently diagnosis is frequently delayed [2] and
monitoring may be challenging. The potential for
patient-reported outcomes to enhance care for these pa-
tients is hitherto unexplored.
GCA is the commonest form of systemic vasculitis in peo-
ple over the age of 50; it is estimated that by 2050, more than 3
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million people will have been diagnosed with GCA in Europe,
North America, and Oceania [3]. GCA classically presents
with headache, jaw claudication, flu-like symptoms, and in-
flammatory pain and stiffness in the shoulders and hips
(polymyalgia rheumatica, present in 50%) [4]. There is a risk
of blindness in 20% of cases if untreated [4, 5].
Glucocorticoids have been the mainstay of treatment for
GCA for decades. Adjuvant immunosuppression using the
IL6-inhibitor tocilizumab (TCZ) has been shown in clinical
trials to reduce the risk of GCA relapse and increases the
chance of sustained glucocorticoid-free remission at 1 year
[6]. On this basis TCZ is now licensed and recommended as
an adjuvant treatment for GCA [7, 8]. Importantly the pivotal
TCZ trial, GiACTA, included patient-reported outcomes as
secondary outcome measures. In contrast trials of methotrex-
ate for GCA gave equivocal results. A conditional recommen-
dation for methotrexate as adjuvant therapy was made [7] on
the basis of an individual patient data analysis of the three
trials. If a common set of patient-reported outcomes had been
measured in each of these trials, this might have given a clear-
er answer on the clinical utility of MTX in GCA.
Takayasu arteritis (TAK) is a rarer form of LVV which
predominantly affects women of childbearing age and in-
volves the aorta and its main branches and the pulmonary
arteries [9]. Takayasu arteritis therefore differ from giant cell
arteritis in terms of age of onset, distribution of arterial in-
volvement, and symptoms. Weight loss, fever, and fatigue
are key constitutional symptoms, while vascular inflammation
and occlusion lead to pain, claudication, and tissue loss [10].
Patients with Takayasu are also treated with glucocorticoids
but in combination with non-biological disease-modifying
agents from the start (as opposed to in GCA where glucocor-
ticoids alone are the standard first line treatments); in relapsing
or refractory patients, TCZ or anti-tumor necrosis factor in-
hibitors are also considered [8].
What Is the Impact on Health-Related Quality of Life?
Having GCA can impact on health-related quality of life due
to symptoms (e.g., pain, visual disturbance and musculoskel-
etal symptoms), glucocorticoids adverse effects, and loss of
feeling “normal”) [11]. Patients are concerned about delays in
getting a diagnosis and also fear going blind [11]. There is an
association between vision-related quality of life scores and
global health-related quality of life in people with GCA [12].
People with GCA ranked the following topics as most impor-
tant to them: “losing sight in both eyes permanently,” “having
intense or severe pain,” and “feeling weak, tired or exhausted”
[13]. There is also the psychological impact of weighing up
fear of treatment with glucocorticoids versus fear of going
blind [14]. Dealing with a chronic illness that runs an unpre-
dictable course frequently demands “work” on the part of the
patient who has to plan their life around an uncertain short-
and long-term future; coming to terms with requirements for
higher dosages of glucocorticoids during active disease is part
of that work in GCA [15]. Interestingly, patients with GCA
who received TCZ in the GIACTA trial reported clinically
meaningful improvements in overall health-related quality of
life and fatigue compared with those receiving glucocorticoids
alone [16]. After 1 year, HRQoL in the treatment group was
the same as age and gender matched controls and exceeded
normal values in some domains [16]. This finding challenges
preconceptions that fatigue and depression, which are charac-
terized by elevation in IL-6 [17], are an inevitable part of
systemic inflammatory diseases such as GCA and TAK; mon-
itoring health-related quality of life may be an efficient way of
assessing how well the underlying inflammatory disease is
being controlled by treatment, particularly since measurement
of acute phase markers in TCZ-treated patients tends to be
clinically uninformative.
People living with TAK have higher levels of anxiety and
depression and greater physical limitations than healthy peo-
ple [18]. People in Turkey who have been diagnosed with
TAK have poorer health-related quality of life than healthy
controls; with scores comparable to people with other inflam-
matory rheumatic conditions such as rheumatoid arthritis [19].
People living in the USA with TAK were found to have
poorer HRQoL if they were taking more immunosuppressants
(this is likely to be related to increased severity of disease) and
if they had active disease or were older age [20].
Recent Findings
How Is Health-Related Quality of Life Measured in the Large
Vessel Vasculitides? Measurement of HRQoL scores in LVV
has mainly been based on generic patient reported outcomes
(PROs), specifically the Short-Form 36 (SF-36) [21]. The
benefits of the SF-36 are that it is a well-recognized and val-
idated outcome measure [21] and allows comparison between
people withLVV, other conditions and general population
controls, for example, in the HRQoL report from the
GIACTA study [16]. Symptom-specific patient-reported out-
comes, for example, the FACIT-Fatigue outcome, have also
been used to compare one aspect of HRQoL [22] within a
randomized controlled trial [16]. Studies in people with
TAK have also used the SF36 to compare with the general
population and other diseases [19].
Because generic PROs have been designed to be relevant
across diseases and populations, there is the potential that face
and content validity of the PRO to people with the disease
under study is reduced [23]. This lack of specificity could
reduce the ability to detect differences in state between people
with the disease and in the same person over time [23]. In
GCA, for example, using known groups analyses, the SF-36
does not detect differences between patients with and without
visual loss or systemic involvement for example [24].
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The development of disease-specific PROs mandates in-
clusion of people with the disease in question at every stage,
in line with FDA guidance [25]. Figure 1 illustrates the differ-
ent stages of PRO development which can be used to develop
disease-specific, generic, or symptom-specific PROs.
Underpinning qualitative research to explore the full range
of impacts of the disease and its treatment to people is per-
formed first to ensure face and content validity of the final
disease-specific PRO [26]. Themes important to people with
the disease are then used as the basis for candidate question-
naire items, including stems and response categories. These
are then piloted with cognitive interviewing techniques to test
understanding, readability, and relevance [27]. Statistical anal-
ysis on data from a large-scale survey to test the PRO ques-
tions is then used to determine the final composition of the
PRO. Exploratory Factor analysis [28] and Rasch analysis
[29] are used to confirm the ideal structure of the PRO, and
tests of validity are performed (e.g., test-retest and know
groups validity) [30, 31]. Disease-specific PROs provide dif-
ferent information to generic and symptom-specific PROs and
are therefore complimentary and can be used together [32].
See Fig. 2 for comparison of generic versus disease specific
PROs.
Disease-Specific PROs in Large Vessel Vasculitis?
The Outcome Measurement in Rheumatology (OMERACT)
is an international collaborative initiative including re-
searchers, clinicians, patient research partners, methodolo-
gists, pharmaceutical industry, and FDA representatives,
working to define core sets of outcome measurements for
use in RCTs, [33].
The OMERACT Vasculitis Working Group published a
core set of domains and outcome measures for use in clinical
trials in LVVin 2017 [34••] and highlighted the lack of a
disease-specific PRO for people with GCA [34••, 35] and
TAK [36]. The OMERACT group proposed a draft core set
of domains for both GCA and TAK, including organ function,
arterial function, biomarkers, fatigue, pain, and death and two
additional preferred domains including psychosocial impact
and physical function, plus separate additional GCA- and
TAK- specific domains. A large-scale validation survey of a
PRO for patients with GCA is currently underway in the UK,
based on underpinning qualitative work in the UK and
Australia [37]. Patient interviews and focus groups in the
USA and Turkey have also identified domains of importance
to patients with TAK [38], including “Pain and Discomfort,”
“Fatigue and Low Energy Levels,” and “Emotional Effects”;
these domains could underpin the development of a future
disease-specific PRO for TAK [38].
How Can we Measure the Patient Experience of Care in Large
Vessel Vasculitis?
PROs measure peoples’ perceptions of their health-related
quality of life, whereas patient-reported experience measures
(PREMs) are questionnaires that focus on the experience of
receiving care. PREMs can be used as an indicator of quality
of care and could be functional (e.g., what facilities were
available and were they available in a timely way?) and/or
relational (e.g., did you feel listened to and included in discus-
sions about your treatment?) [39]. PREMs should also be
underpinned by patient stakeholder involvement at each stage,
as described in the development and validation of a PREM for
patients with rheumatoid arthritis [40]. At present there is no
PREM for either GCA or TAK, but this could be an important
project for the future, particularly in view of the substantial
variability and delays involved in getting a diagnosis [2]. A
PREM may also be used to compare fast-track and conven-
tional care strategies. See Fig. 2 for overview of difference
between PROs and PREMs.
Fig. 1 Development of a patient reported outcome measure
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What Is the Future for PROs for Large Vessel
Vasculitis?
There is an ongoing need for generic, symptom, and disease-
specific PROs for use in future clinical trials and observational
studies inLVV. We know that people with vasculitis and their
physicians rank outcomes of importance in different ways
[41]; PROs are an important way of ensuring the patient per-
spectives are always included. Glucocorticoids have been the
mainstay of treatment for both GCA and TAK, with the im-
pact on people taking these medications quite significant [15].
A novel treatment-specific PRO to measure impact of
glucocorticoids on people with rheumatic disease is also
c u r r e n t l y und e rway , l e d by t h e OMERACT
Glucocorticoid working group [42]. This will comple-
ment the Glucocorticoid Toxicity Index (GTI), which
is a clinician derived tool and not a PRO.
Use of Individual Level PROs for Patient Care in Large
Vessel Vasculitis? Future Opportunities?
Individual-level PROs can be used to monitor symptoms re-
motely, improve patient-clinician communication on impor-
tant issues related to their health-related quality of life, and
help promote self-management care [43••]. Using PROs with-
in routine clinical care has been explored in other diseases, for
example, the use of PROMIS symptom measures recorded on
tablets prior to consultations in primary care; challenges in-
cluded under documentation or under use of scores to change
clinical practice, felt to be related to time constraints in prima-
ry care and lack of clinician support [44]. Qualitative analysis
of a trial using daily completion of the Remote Monitoring of
RA smartphone app over 4 weeks (patients reminded each day
with a buzzer) with a physician review at the end of the
4 weeks, identified that patients reported that they felt their
RA was “more visible” to clinicians and captured the bigger
picture of their disease [45]. A year-long European study into
use of E-PROs also found them to be acceptable to patients
with RA, although some challenges, including lack of engage-
ment by patients over the longer-term, particularly during pe-
riods of remission and if their clinicians did not act on the
feedback provided were also identified [46]. There may be
technical issues given that GCA patients may be an older
age groups and therefore may not wish to complete PROs
online. Patients with LVV may however wish to reduce the
frequency of their face to face consultations because of the
immunosuppressant effect of their diseases and treatments,
impact of comorbidities such as cardiovascular disease and
in the case of GCA, older age. Further work to explore the
use of E-PROs and identify potential barriers and opportuni-
ties will need to be completed within these specific popula-
tions; it is likely that not all patients will feel the same about
the use of EPROs and it will be important not to exclude any
vulnerable groups due to their routine use in clinical practice.
Conclusion
Generic PROs such as the SF-36 are already used routinely in
clinical trials and observational studies in GCA and TAK to
measure the impact on health-related quality of life. The de-
velopment of disease-specific and treatment-specific PROs is
Fig. 2 Overview of patient reported outcome (PRO) measures and
patient-reported experiences measures (PREMs). SF-36: Short-form
36; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy-
Fatigue scale; GCA PRO: Patient reported outcome for people with giant
cell arteritis; RA PREM: patient reported experience measure for people
with rheumatoid arthritis and other rheumatic diseases
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underway. Future directionsmay include the use of E-PROs to
facilitate remote consultations and the development of
PREMs to allow measurement and improvement of care path-
ways for people with large vessel vasculitis.
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